Repurposing doxycycline for synucleinopathies: remodelling of α-synuclein oligomers towards non-toxic parallel beta-sheet structured species
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Synucleinophaties are progressive neurodegenerative disorders with no cure to date. An attractive strategy to tackle this problem is repurposing already tested safe drugs against novel targets. In this way, doxycycline prevents neurodegeneration in Parkinson models by modulating neuroinflammation. However, anti-inflammatory therapy per se is insufficient to account for neuroprotection. Herein we characterise novel targets of doxycycline describing the structural background supporting its effectiveness as a neuroprotector at subantibiotic doses. Our results show that doxycycline reshapes α-synuclein oligomers into off-pathway, high-molecular-weight species that do not evolve into fibrils. Off-pathway species present less hydrophobic surface than on-pathway oligomers and display different β-sheet structural arrangement. These structural changes affect the α-synuclein ability to destabilize biological membranes, cell viability, and formation of additional toxic species. Altogether, these mechanisms could act synergically giving novel targets for repurposing this drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, recent studies demonstrated that DOX reduces the size and load of α-synuclein oligomers by converting them into high-molecular weight species that are not able to form fibrils, thus increasing cell viability [282,284].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [284]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mosmann, T. (1983) · Journal of Immunological Methods · doi:10.1016/0022-1759(83)90303-4 · Cited by 56,104
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Molecular Mechanisms of Stress-Responsive Changes in Collagen and Elastin Networks in Skin
Aziz, J., Shezali, H., Radzi, Z., Yahya, N. A., Abu Kassim, N. H., Czernuszka, J., & Rahman, M. T. (2016) · Skin Pharmacology and Physiology · doi:10.1159/000447017 · Cited by 7,323
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Svergun, D. I. (1992) · Journal of Applied Crystallography · doi:10.1107/s0021889892001663 · Cited by 3,759
Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., & Goedert, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6469 · Cited by 2,868
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
Luk, K. C., Kehm, V., Carroll, J., Zhang, B., O’Brien, P., Trojanowski, J. Q., & Lee, V. M.-Y. (2012) · Science · doi:10.1126/science.1227157 · Cited by 2,563
Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases
Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurdo, J., Taddei, N., Ramponi, G., Dobson, C. M., & Stefani, M. (2002) · Nature · doi:10.1038/416507a · Cited by 2,434
[18] Quantification of β-sheet amyloid fibril structures with thioflavin T
LeVine, H. (1999) · Methods in Enzymology · doi:10.1016/s0076-6879(99)09020-5 · Cited by 1,365
Cited by
Old Drugs as New Treatments for Neurodegenerative Diseases
Durães, F., Pinto, M., & Sousa, E. (2018) · Pharmaceuticals · doi:10.3390/ph11020044 · Cited by 343
“Furthermore, doxycycline (10) has only been reported to bind to oligomeric species of α-synuclein; the physiological monomeric forms are preserved [77].”
BackgroundGut microbiome and Parkinson's disease: Perspective on pathogenesis and treatment
Salim, S., Ahmad, F. A., Banu, A., & Mohammad, F. (2022) · Journal of Advanced Research · doi:10.1016/j.jare.2022.10.013 · Cited by 133
Alpha Synuclein: Neurodegeneration and Inflammation
Forloni, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065914 · Cited by 122
Tetracycline repurposing in neurodegeneration: focus on Parkinson’s disease
Bortolanza, M., Nascimento, G. C., Socías, S. B., Ploper, D., Chehín, R. N., Raisman‐Vozari, R., & Bel, E. A. D. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1913-1 · Cited by 109
Self-citationVaresi, A., Campagnoli, L. I. M., Fahmideh, F., Pierella, E., Romeo, M., Ricevuti, G., Nicoletta, M., Chirumbolo, S., & Pascale, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012289 · Cited by 88
Doxycycline Inhibits α-Synuclein-Associated Pathologies in Vitro and in Vivo
Dominguez-Meijide, A., Parrales, V., Vasili, E., González-Lizárraga, F., König, A., Lázaro, D. F., Lannuzel, A., Haik, S., Del Bel, E., Chehín, R., et al. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105256 · Cited by 81
Self-citationTosato, M., & Marco, V. D. (2019) · Biomolecules · doi:10.3390/biom9070269 · Cited by 78
Lucchetti, J., Fracasso, C., Balducci, C., Passoni, A., Forloni, G., Salmona, M., & Gobbi, M. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.252064 · Cited by 75
“…results in brain concentrations always lower than 1 mM, i.e., lower than the concentrations required for antiaggregating effects in vitro ($10 mM) (Forloni et al., 2001, 2002; Cardoso et al., 2003; Giorgetti et al., 2011; Ward et al., 2011; De Luigi et al., 2015; Gonzalez-Lizarraga et al., 2017).”
BackgroundThe neuroprotective effect of doxycycline on neurodegenerative diseases
Santa-Cecília, F. V., Leite, C. A., Del-Bel, E., & Raisman-Vozari, R. (2019) · Neurotoxicity Research · doi:10.1007/s12640-019-00015-z · Cited by 73
Self-citationLorente-Picón, M., & Laguna, A. (2021) · Biomolecules · doi:10.3390/biom11030433 · Cited by 69
“Recent in vitro studies have shown that DOX induced the reshaping of α-syn oligomers so that they did not evolve into fibrils, thus affecting αsyn ability to destabilize biological membranes, cell viability, and seeding capacity [218].”
BackgroundMicroglial glutamate release evoked by α‐synuclein aggregates is prevented by dopamine
Pereira, M. D. S., Acuña, L., Hamadat, S., Rocca, J., González‐Lizárraga, F., Chehín, R. N., Sepulveda-Diaz, J. E., Bel, E. A. D., Raisman‐Vozari, R., & Michel, P. P. (2018) · Glia · doi:10.1002/glia.23472 · Cited by 63
“Human αS was expressed in Escherichia coli using the pT7-7 expression plasmid and purified as described (Hoyer et al., 2002; Kaylor et al., 2005; González-Lizárraga et al., 2017).”
MethodSelf-citationAcuña, L., Hamadat, S., Corbalán, N. S., González-Lizárraga, F., dos-Santos-Pereira, M., Rocca, J., Sepúlveda Díaz, J., Del-Bel, E., Papy-García, D., Chehín, R. N., et al. (2019) · Cells · doi:10.3390/cells8080776 · Cited by 62
“Recombinant monomeric αS (αSm) (70 μg/ml) was agitated by orbital shaking as previously described [10], and aggregation kinetics monitored by measurement of Thioflavin T (ThT) fluorescence [27] (not shown).”
MethodSelf-citationCerium oxide NPs mitigate the amyloid formation of α-synuclein and associated cytotoxicity
Zand, Z., Khaki, P. A., Salihi, A. B., Sharifi, M., Nanakali, N. M. Q., Al-Asady, A. A., Aziz, F. M., Shahpasand, K., Hasan, A., & Falahati, M. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s220380 · Cited by 62
“4, 20 mM, 150 mM NaCl) at 37°C at 700 rev/min based on the reported paper.(23) To monitor the impact of CeO2 NPs on protein aggregation, α-syn samples with a single fixed concentration of CeO2 NPs (40 μg/ mL) (as the highest dose which does not show agglomeration) were co-incubated during the preparation of fibrils of…”
MethodOrtega-Ramírez, A., Vega, R., & Soto, E. (2017) · Mediators of Inflammation · doi:10.1155/2017/3728096 · Cited by 63
“Furthermore, there is a trend to search for multitarget molecules that may reach an efficient neuroprotective effect [161].”
BackgroundMitochondria and Antibiotics: For Good or for Evil?
Suarez-Rivero, J. M., Pastor‐Maldonado, C. J., Povea-Cabello, S., Álvarez-Córdoba, M., Villalón-García, I., Talaverón-Rey, M., Suárez-Carrillo, A., Munuera-Cabeza, M., & Sánchez-Alcázar, J. A. (2021) · Biomolecules · doi:10.3390/biom11071050 · Cited by 62
“Several studies have proposed tetracyclines and derivatives, such as doxycycline and minocycline, as neuroprotector antibiotics through several mechanisms: their anti-inflammatory properties [41]; their ability to protect dopaminergic neurons in the substantia nigra [185]; the fact that they regulate the glial respons…”
BackgroundSocías, S. B., González‐Lizárraga, F., Ávila, C. L., Vera, C., Acuña, L., Sepulveda-Diaz, J. E., Bel, E. A. D., Raisman‐Vozari, R., & Chehín, R. N. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.12.002 · Cited by 60
Self-citationModification of the gut microbiome to combat neurodegeneration
Sasmita, A. O. (2019) · Reviews in the Neurosciences · doi:10.1515/revneuro-2019-0005 · Cited by 43
Simultaneous Determination of the Size and Shape of Single α-Synuclein Oligomers in Solution
Awasthi, S., Ying, C., Li, J., & Mayer, M. (2023) · ACS Nano · doi:10.1021/acsnano.3c01393 · Cited by 56
Drug repurposing in neurological diseases: an integrated approach to reduce trial and error
Clout, A. E., Pasqua, O. E. D., Hanna, M. G., Orlu, M., & Pitceathly, R. D. S. (2019) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-320879 · Cited by 55
Ubiquitin biology in neurodegenerative disorders: From impairment to therapeutic strategies
Kumar, D., Ambasta, R. K., & Kumar, P. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101078 · Cited by 54
Pantazopoulou, M., Brembati, V., Kanellidi, A., Bousset, L., Melki, R., & Stefanis, L. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15174 · Cited by 52
“The authors showed that doxycycline (100–400 μM) reshapes α-Syn into non-toxic oligomers, inhibiting its further fibrillation (Gonzalez-Lizarraga et al., 2017).”
BackgroundRahmani, M., Negro, S., & Barcia, E. (2022) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2022.106237 · Cited by 47
Inflammation and Parkinson's disease pathogenesis: Mechanisms and therapeutic insight
Forloni, G., Vitola, P. L., Cerovic, M., & Balducci, C. (2020) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2020.11.001 · Cited by 45
Evolving Landscape of Parkinson’s Disease Research: Challenges and Perspectives
Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2025) · ACS Omega · doi:10.1021/acsomega.4c09114 · Cited by 45
Liu, W., Wang, G., Wang, Z., Wang, G., Huang, J., & Liu, B. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.04.003 · Cited by 44
Potent inhibitors of toxic alpha-synuclein identified via cellular time-resolved FRET biosensors
Braun, A. R., Liao, E. E., Horvath, M., Kalra, P., Acosta, K., Young, M. C., Kochen, N. N., Lo, C. H., Brown, R. Z., Evans, M. D., et al. (2021) · npj Parkinson s Disease · doi:10.1038/s41531-021-00195-6 · Cited by 41
Gilan, S. S. T., Rayat, D. Y., Mustafa, T. A., Aziz, F. M., Shahpasand, K., Akhtari, K., Salihi, A. B., Abou‐Zied, O. K., & Falahati, M. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s212387 · Cited by 37
“4 and agitated at 700 rev/ min at 37 °C in the the presence of ZVFe NPs adapted from a previous study.(22) ZVFe NPs concentration was also set to 50 μg/mL.”
MethodGut brain axis: an insight into microbiota role in Parkinson’s disease
Moustafa, S. A., Abdou, S. M., Dawood, A. S., Azar, J., Elmorsy, E. M., Rizk, N., & Salama, M. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00808-2 · Cited by 37
Challenges of Repurposing Tetracyclines for the Treatment of Alzheimer’s and Parkinson’s Disease
Markulin, I., Matasin, M., Turk, V. E., & Salković-Petrisic, M. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-021-02457-2 · Cited by 36
Doxycycline Interferes With Tau Aggregation and Reduces Its Neuronal Toxicity
Medina, L., González‐Lizárraga, F., Dominguez‐Meijide, A., Ploper, D., Parrales, V., Sequeira, S., Cima‐Omori, M., Zweckstetter, M., Bel, E. A. D., Michel, P. P., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.635760 · Cited by 35
“This effect is distinct from what has been previously reported for doxycycline on α-synuclein aggregation, where only oligomers are observed (González-Lizárraga et al., 2017).”
BackgroundResultSelf-citationBleomycin modulates amyloid aggregation in β-amyloid and hIAPP
Kumari, A., Sharma, R., Shrivastava, N., Somvanshi, P., & Grover, A. (2020) · RSC Advances · doi:10.1039/d0ra04949b · Cited by 34
Bortolanza, M., do Nascimento, G. C., Raisman‐Vozari, R., & Del‐Bel, E. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15439 · Cited by 33
“In addition to its anti-inflammatory effect, doxycycline reshapes α-synuclein oligomers and inhibits α-synuclein aggregation and the seeding of new oligomers (González-Lizárraga et al., 2017; Ruzza et al., 2014).”
BackgroundSelf-citationMicrobiome-based therapeutics for Parkinson's disease
Hamilton, A. M., Krout, I. N., White, A. C., & Sampson, T. R. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00462 · Cited by 33
Multiple Protective Roles of Nanoliposome‐Incorporated Baicalein against Alpha‐Synuclein Aggregates
Aliakbari, F., Mohammad‐Beigi, H., Abbasi, S., Rezaei‐Ghaleh, N., Lermyte, F., Parsafar, S., Becker, S., Tafreshi, A. P., O’Connor, P. B., Collingwood, J. F., et al. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202007765 · Cited by 33
Hernández‐Parra, H., Cortés, H., Ávalos‐Fuentes, J. A., Prado-Audelo, M. L. D., Florán, B., Leyva‐Gómez, G., Sharifi‐Rad, J., & Cho, W. C. S. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01612-5 · Cited by 34
Pan, Q., Ban, Y., & Khan, S. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.03.186 · Cited by 32
Filho, A. J. M. C., Cunha, N. L., Rodrigues, P. D. A., de Souza, A. G., Soares, M. V.-R., Jucá, P. M., de Queiroz, T., Clemente, D. C. D. S., Mottin, M., Andrade, C. H., et al. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.11.007 · Cited by 34
Pang, C., Zhang, N., & Falahati, M. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.12.130 · Cited by 30
Tourville, A., Viguier, S., González‐Lizárraga, F., Tomas‐Grau, R. H., Ramírez, P., Brunel, J. M., Pereira, M. D. S., Bel, E. A. D., Chehín, R. N., Ferrié, L., et al. (2023) · Antioxidants · doi:10.3390/antiox12030575 · Cited by 29
“In addition, DOX was reported to prevent amyloid aggregation of αS [11] and restrain neurodegenerative changes induced by aggregated forms of αS [12].”
BackgroundSelf-citationModulation of α-Synuclein Fibrillation by Ultrasmall and Biocompatible Gold Nanoclusters
Mahapatra, A., Sarkar, S., Biswas, S. C., & Chattopadhyay, K. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00550 · Cited by 29
Ferreira‐Junior, N. C., Pereira, M. D. S., Francis, N., Ramírez, P., Martorell, P., González‐Lizárraga, F., Figadère, B., Chehín, R. N., Bel, E. A. D., Raisman‐Vozari, R., et al. (2021) · Cells · doi:10.3390/cells10082163 · Cited by 29
“Interestingly, DOX was also found capable of preventing amyloid aggregation of α Synuclein (αS) and tau, two seeding-prone proteins involved in PD [12,13] and Alzheimer’s disease [14] pathologies, respectively, suggesting that this tetracycline has the potential of a multimodal neuroprotective drug.”
BackgroundMethodSelf-citationAxon Guidance Molecules and Pain
Damo, E., & Simonetti, M. (2022) · Cells · doi:10.3390/cells11193143 · Cited by 28
“Astroglia are assumed to be the main source of Wnt ligands in the spinal cord, and harboring a wide variety of Wnt receptors, they are considered the main actor in the multidirectional astrocyte-neuron-microglia crosstalk [61,62].”
BackgroundScanavachi, G., Espinosa, Y. R., Yoneda, J. S., Rial, R., Ruso, J. M., & Itri, R. (2020) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2020.03.059 · Cited by 28
Self-citationPotential effectiveness and adverse implications of repurposing doxycycline in COVID-19 treatment
Narendrakumar, L., Joseph, I., & Thomas, S. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1865803 · Cited by 25
“2 Anti-inflammatory Inhibit IL-6 and TNF-α [30] 3 Neuroprotective effects Anti-inflammatory property [24]”
BackgroundMello, B. S. F., Filho, A. J. M. C., Custódio, C. S., Rodrigues, P. D. A., Carletti, J. V., Vasconcelos, S. M. M., de Sousa, F. C. F., Sanders, L. L. O., & Macêdo, D. S. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.05.083 · Cited by 26
CMT-3 targets different α-synuclein aggregates mitigating their toxic and inflammogenic effects
González‐Lizárraga, F., Ploper, D., Ávila, C. L., Socías, S. B., Pereira, M. D. S., Machín, B., Bel, E. A. D., Michel, P. P., Pietrasanta, L. I., Raisman‐Vozari, R., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-76927-0 · Cited by 23
Self-citationPAMAM dendrimers of generation 4.5 loaded with curcumin interfere with α-synuclein aggregation
Igartúa, D. E., González‐Lizárraga, F., Martinez, C. S., Alonso, S. D. V., Ávila, C. L., Chehín, R. N., Chiaramoni, N. S., & Prieto, M. J. (2023) · OpenNano · doi:10.1016/j.onano.2023.100140 · Cited by 23
Self-citationAmaral, L. D., Santos, N. A. G. D., Sisti, F. M., Del Bel, E., & Santos, A. C. D. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109454 · Cited by 18
Lyu, J., Long, X., Xie, T., Jiang, G., Jiang, J., Ye, L., & Li, Q. (2020) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2020.115051 · Cited by 18
Lee, J. H., Han, J., Joe, E.-H., & Jou, I. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00747-1 · Cited by 18
“In this study, we identified doxycycline can disrupt SHP‑mediated XBP1 SUMOylation and may therefore have therapeutic activity in PD caused by the LRRK2‑GS mutation remodeling α-synuclein early aggregates, and scavenging ROS [2, 13, 18, 22].”
BackgroundRepositioning doxycycline for treating synucleinopathies: Evidence from a pre-clinical mouse model
Vitola, P. L., Artioli, L., Cerovic, M., Poletto, C., Dacomo, L., Leva, S., Balducci, C., & Forloni, G. (2022) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2022.105229 · Cited by 18
Mahapatra, A., Sarkar, S., Biswas, S. C., & Chattopadhyay, K. (2019) · Chemical Communications · doi:10.1039/c9cc04251b · Cited by 17
Shen, S., Zhang, C., Xu, Y.-M., & Shi, C.-H. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212929 · Cited by 17
Cortez-Maya, S., Moreno-Herrera, A., Palos, I., & Rivera, G. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190628163633 · Cited by 17
Lautenschläger, J., & Schierle, G. S. K. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101660 · Cited by 16
Mullis, A. S., Schlichtmann, B. W., Narasimhan, B., Cademartiri, R., & Mallapragada, S. K. (2018) · Biomedical Materials · doi:10.1088/1748-605x/aaa778 · Cited by 15
Recent Advances in Drug Repurposing for Parkinson’s Disease
Chen, X., Gumina, G., & Virga, K. G. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180719144850 · Cited by 15
Minocycline, but not doxycycline attenuates NMDA-induced [Ca2+]i and excitotoxicity
Lu, Y., Yang, Y., Chen, W., Du, N., Du, Y., Gu, H., & Liu, Q. (2020) · Neuroreport · doi:10.1097/wnr.0000000000001558 · Cited by 15
Lessons learned from protein aggregation: toward technological and biomedical applications
Ávila, C. L., Chaves, S., Socías, S. B., Pingitore, E. V., González‐Lizárraga, F., Vera, C., Ploper, D., & Chehín, R. N. (2017) · Biophysical Reviews · doi:10.1007/s12551-017-0317-z · Cited by 15
Self-citationDrug repositioning for Parkinson’s disease: An emphasis on artificial intelligence approaches
Karimi-Sani, I., Sharifi, M., Abolpour, N., Lotfi, M., Atapour, A., Takhshid, M. A., & Sahebkar, A. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102651 · Cited by 14
Astrocytes, a Promising Opportunity to Control the Progress of Parkinson’s Disease
Sánchez, A., Moráles, I., Rodriguez‐Sabate, C., Solé-Sabater, M., & Rodríguez, M. (2021) · Biomedicines · doi:10.3390/biomedicines9101341 · Cited by 14
“Doxycycline is perhaps the most promising drug to prevent the M1 pro-inflammatory actions and protecting DA-cells in in vitro and in vivo animal models of PD [64,65].”
BackgroundDoxycycline to treat levodopa-induced dyskinesias in Parkinson's disease: a preliminary study
Santos‐Lobato, B. L., Brito, M. M. C. M., Pimentel, Â. V., Cavalcanti, R. T. O., Del-Bel, E., & Tumas, V. (2023) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0043-1768668 · Cited by 14
“23 Also, the absence of a control group in our study might cause an improvement in LID due to the placebo effect.”
BackgroundSelf-citationNapp, A., Houbart, V., Demelenne, A., Merville, M., Crommen, J., Dumoulin, M., Garraux, G., Servais, A., & Fillet, M. (2018) · Electrophoresis · doi:10.1002/elps.201800224 · Cited by 14
Chakraborty, R., Sahoo, S., Halder, N., Rath, H., & Chattopadhyay, K. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00436 · Cited by 14
New Approaches to Profile the Microbiome for Treatment of Neurodegenerative Disease
Elmaleh, D. R., Downey, M. A., Kundakovic, L., Wilkinson, J. E., Neeman, Z., & Segal, E. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210198 · Cited by 14
Tomas‐Grau, R. H., González‐Lizárraga, F., Ploper, D., Ávila, C. L., Socías, S. B., Besnault, P., Tourville, A., Mella, R. M., Villacé, P., Salado, C., et al. (2022) · Cells · doi:10.3390/cells11172759 · Cited by 14
Self-citationGonçalves, A. M. R., Pereira-Santos, A. R., Esteves, A. R., Cardoso, S. M., & Empadinhas, N. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7997 · Cited by 14
“Dox-ycycline was suggested to reshape a -synuclein oligomers into noncytotoxic species (59).”
Doxycycline: An essential tool for Alzheimer’s disease
Forloni, G. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118159 · Cited by 12
Pre-aggregation kinetics and intermediates of α-synuclein monitored by the ESIPT probe 7MFE
Fauerbach, J. A., & Jovin, T. M. (2017) · European Biophysics Journal · doi:10.1007/s00249-017-1272-0 · Cited by 12
Palomino‐Hernández, O., Buratti, F. A., Sacco, P. S., Rossetti, G., Carloni, P., & Fernández, C. O. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145061 · Cited by 12
Stalder, P., Serdiuk, T., Ghosh, D., Fleischmann, Y., Ait‐Bouziad, N., Quast, J.-P., Malinovska, L., Ouared, A., Davranche, A., Haenseler, W., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-00966-5 · Cited by 11
“PEP in cyan.”
Antimicrobial and Hemostatic Diatom Biosilica Composite Sponge
Youn, S., Ki, M., Min, K. H., Abdelhamid, M. A. A., & Pack, S. P. (2024) · Antibiotics · doi:10.3390/antibiotics13080714 · Cited by 11
“It has also been reported to limit amyloid-like aggregation of α -synuclein and reduce inflammatory processes associated with neurodegeneration [39]. neuro-degeneration [39].”
BackgroundSingh, S., & Chauhan, K. (2022) · International Journal of Neuroscience · doi:10.1080/00207454.2022.2154670 · Cited by 11
“…addition, doxycycline inhibits α-synuclein aggregation by formation of α-synuclein oligomer which does not form fibril (insol-uble toxic product) [ 9 ]. tocopherol is a naturally occurring vitamin e that belongs to the class of organic chemical compounds. tocopherol is a useful antioxidant and…”
Neurodegeneration, Mitochondria, and Antibiotics
Suarez-Rivero, J. M., López‐Pérez, J., Muela‐Zarzuela, I., Pastor‐Maldonado, C. J., Cilleros-Holgado, P., Gómez-Fernández, D., Álvarez-Córdoba, M., Munuera-Cabeza, M., Talaverón-Rey, M., Povea-Cabello, S., et al. (2023) · Metabolites · doi:10.3390/metabo13030416 · Cited by 10
The effects of microbiota abundance on symptom severity in Parkinson’s disease: A systematic review
Papić, E., Rački, V., Hero, M., Tomić, Z., Čizmarević, N. S., Kovanda, A., Kapović, M., Hauser, G., Peterlin, B., & Vuletić, V. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1020172 · Cited by 10
“For example, potential beneficial effects have been proposed in the application of antibiotics (Li et al., 2004; González-Lizárraga et al., 2017; Pu et al., 2019), probiotics (Cassani et al.”
BackgroundButnaru, D., & Chapman, J. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.09.009 · Cited by 10
Rose, C., Tomas‐Grau, R. H., Zabala, B., Michel, P. P., Brunel, J. M., Chehín, R. N., Raisman‐Vozari, R., Ferrié, L., & Figadère, B. (2024) · ChemMedChem · doi:10.1002/cmdc.202300597 · Cited by 9
Self-citationRedesigning the kinetics of lysozyme amyloid aggregation by cephalosporin molecules
Muthu, S. A., Qureshi, A., Sharma, R., Bisaria, I., Parvez, S., Grover, S., & Ahmad, B. (2024) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2024.2335304 · Cited by 8
“Molecules of the tetracycline group successfully inhibit aggregation of amyloid-b (Forloni et al., 2001), a -synu- clein (Gonz � alez-Liz � arraga et al., 2017), transthyretin (Cardoso et al., 2003), b 2-macroglobulin (Giorgetti et al., 2011), are under clinical studies to combat Alzheimer’s…”
Ploper, D., Pernicone, A. O., Tomas‐Grau, R. H., Manzano, V. E., Socías, S. B., Terán, M. D. M., Isa, V. B., Sosa‐Padilla, B., González‐Lizárraga, F., Ávila, C. L., et al. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00169 · Cited by 8
Self-citationOligomeropathies, inflammation and prion protein binding
Forloni, G., Vitola, P. L., & Balducci, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.822420 · Cited by 8
“It is interesting to note that doxycycline can change the structure of α-synOs into off-pathway, high-molecular-weight species, that do not evolve into fibrils (González-Lizárraga et al., 2017).”
Backgrounddo Amaral, L., dos Santos, N. A. G., Sisti, F., Bel, E. A. D., & dos Santos, A. C. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02435-3 · Cited by 8
Nascimento, G. C., Bortolanza, M., Bribián, A., Leal-Luiz, G., Raisman‐Vozari, R., López‐Mascaraque, L., & Bel, E. A. D. (2023) · ASN NEURO · doi:10.1177/17590914231155976 · Cited by 7
Self-citationEffects of Doxycycline in Swiss Mice Predictive Models of Schizophrenia
Issy, A. C., Pedrazzi, J. F. C., van Oosten, A. B. S., Checheto, T., Silva, R. R., Noël, F., & Del-Bel, E. (2020) · Neurotoxicity Research · doi:10.1007/s12640-020-00268-z · Cited by 7
“Recently, doxycycline has also been suggested for the management of neurodegenerative disorders, including Parkinson’s disease (Lazzarini et al. 2013; González-Lizárraga et al. 2017).”
BackgroundSelf-citationPolymyxin B accelerates the α-synuclein aggregation
Mohapatra, A., Bohara, V. S., Kumar, S., & Chaudhary, N. (2021) · Biophysical Chemistry · doi:10.1016/j.bpc.2021.106628 · Cited by 7
Microbial diversity in drug-naïve Parkinson’s disease patients
Papić, E., Rački, V., Hero, M., Zimani, A. N., Sajko, M. Č., Rožmarić, G., Čizmarević, N. S., Ostojić, S., Kapović, M., Hauser, G., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0328761 · Cited by 6
“Antibiotics have also been researched for microbiome-related treatment in PD, with examples such as rifampicin and doxycycline, which demonstrated reduction of alpha-synuclein oligomers forming fibrils in vitro [98].”
Drug repurposing and nanoparticles: New strategies against leishmaniasis
Casadei, B. R., Lotierzo, M. C. G., Malheiros, B., & Barbosa, L. R. S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821100-7.00007-8 · Cited by 6
Self-citationYoon, S. E., Kim, Y., Kim, H., Kwon, H., Kim, U., Lee, S. Y., Park, J. H., Seo, H., Kwak, S. K., Kim, S., et al. (2023) · Small · doi:10.1002/smll.202207511 · Cited by 5
González, N., Gentile, I., Garro, H. A., Delgado‐Ocaña, S., Ramunno, C. F., Buratti, F. A., Griesinger, C., & Fernández, C. O. (2019) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-019-01711-z · Cited by 5
Terán, M. D. M., Tomas‐Grau, R. H., Soliz-Santander, S. E., Guayán, M. L., Isa, V. B., Mercado, A. L., Ávila, C. L., Sosa‐Padilla, B., Cruz, H., Ciss, I., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-15991-w · Cited by 4
Self-citationNeuroprotection in Parkinson Disease
Jain, K. K. (2019) · Springer protocols handbooks/Springer protocols · doi:10.1007/978-1-4939-9465-6_7 · Cited by 4
Singh, S. L., & Bhat, R. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00793 · Cited by 4
Azithromycin combined with doxycycline in non‑gonococcal urethritis
Lu, Z., Hou, M., Li, D., Cheng, J., Deng, H., & Yan, J. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9125 · Cited by 4
“Doxycycline is a long-acting tetracycline-based broadspectrum antibiotic and has a high fat solubility (7,8).”
BackgroundLewis, S. J. G., Sue, C. M., Cooper, A. A., & Halliday, G. M. (2025) · BMJ Neurology Open · doi:10.1136/bmjno-2025-001070 · Cited by 3
“Preclinical work has shown that doxycycline reshapes α -synuclein oligomers into off-pathway species that do not evolve into fibrils, 6 while ambroxol can enhance the enzymatic activity of both wild-type and mutant glucocerebrosidase (GCase).”
Doxycycline Therapeutic Approach in Parkinson’s Disease and L-DOPA-Induced Dyskinesia
Del-Bel, E., Bortolanza, M., Nascimento, G. C., Raisman‐Vozari, R., Pereira, M. D. S., González‐Lizárraga, F., Parrales, V., Michel, P. P., Ploper, D., Ávila, C. L., et al. (2022) · Springer eBooks · doi:10.1007/978-3-031-15080-7_215 · Cited by 3
Self-citationMagnetic amyloid-based biocatalyst for the hydrolysis of urea
Collado, A. D. A. M., Socías, S. B., González‐Lizárraga, F., Ploper, D., Pingitore, E. V., Chehín, R. N., & Chaves, S. (2023) · Food Chemistry · doi:10.1016/j.foodchem.2023.136830 · Cited by 2
Self-citationMachín, B., Soliz-Santander, S. E., Pernicone, A. O., Vélez, E. M. D. M., Manzano, V. E., González‐Lizárraga, F., Madrid, R. E., Ávila, C. L., Pingitore, E. V., Varela, Ó. S., et al. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00547 · Cited by 2
Self-citationde Oliveira, J. L. S., Júnior, G. A. D. C. T., Bonfim, D. A., Júnior, C. M. R. C., Santos, J. A., Ferreira, M. S. D. S., & Júnior, A. D. F. S. (2020) · Dissolution Technologies · doi:10.14227/dt270220p32 · Cited by 2
Management with antibiotics in Parkinson's disease
Bortolanza, M., Santos‐Lobato, B. L., Nascimento, G. C., & Bel, E. A. D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815946-0.00029-6 · Cited by 2
Neurodegenerative Diseases and the Gut Microbiota
Cabré, S., O’Riordan, K. J., & Cryan, J. F. (2022) · Progress in inflammation research · doi:10.1007/978-3-030-91051-8_11 · Cited by 2
Decoding Amyotrophic Lateral Sclerosis: A Systems Biology Approach
Lombard, J., & Hamper, M. (2022) · Journal of Restorative Medicine · doi:10.14200/jrm.2022.0001 · Cited by 2
“Subantibiotic doses of doxycycline also appear to be high enough to interfere with the production of α-synuclein toxic species, the pathological aggregate in Parkinson disease pathogenesis.(77) However, multiple bacterial organisms have developed different mechanisms of resistance mediated by drug efflux mechanisms in…”
Background
Metadata
- Authors
- González-Lizárraga, F., Socías, S. B., Ávila, C. L., Torres-Bugeau, C. M., Barbosa, L. R. S., Binolfi, A., Sepúlveda-Díaz, J. E., Del-Bel, E., Fernandez, C. O., Papy-Garcia, D., Itri, R., Raisman-Vozari, R., & Chehín, R. N.
- Affiliations
- National University of Tucumán (AR)
- Universidade de São Paulo (BR)
- Corresponding author
- Chehín, Rosana N.
- Venue
- Scientific Reports
- Published
- 2017-02-03
- Volume
- 7
- Issue
- 1
- Pages
- 41755-41755
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC5290535
- OpenAlex
- W2584036292
- Cited by
- 119
- References
- 61
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 6 · 2023: 13 · 2022: 18 · 2021: 21 · 2020: 23 · 2019: 13 · 2018: 8 · 2017: 4
- FWCI
- 9.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Americanae (AECID Library) (publishedVersion, other-oa)
- HAL (submittedVersion, cc-by)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by)
- Greater South Information System
- Funders
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2014/)
- Consejo Nacional de Investigaciones Científicas y Técnicas (PIP-CONICET 0183)
- Ministerio de Ciencia, Tecnología e Innovación Productiva
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Campus France
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- doxycycline, drug repurposing, synucleinopathies, alpha-synuclein oligomers, Parkinson's disease, neuroprotection, membrane perturbation, neuroinflammation, hydrophobic surfaces, neurodegeneration
- MeSH terms
- Protein Conformation, beta-Strand, Cell Survival, Doxycycline, Humans, Models, Molecular, Magnetic Resonance Spectroscopy, Protein Binding, Spectroscopy, Fourier Transform Infrared, Neurodegenerative Diseases, Cell Line, Tumor, alpha-Synuclein, Protein Multimerization, Drug Repositioning, Protein Aggregation, Pathological, Protein Aggregates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.